Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma - Wikidata - awgldk - TriplyDB

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

http://www.wikidata.org/entity/Q35791225

about

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?Targeted therapies and immunotherapy in non-small-cell lung cancer Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients.Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.A retrospective analysis of the clinicopathological and molecular characteristics of pulmonary blastoma.Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.Discovery of a potent dual ALK and EGFR T790M inhibitor.Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma.Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis.Commentary on tumor heterogeneity.Reply to Chou et al 'Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution' Mod Pathol 2017; in press.FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma.Longitudinal multi-parametric imaging in radiation oncology: boon or bane?The promise of multiparametric imaging in oncology: how do we move forward?A Convergence-Based Framework for Cancer Drug Resistance.Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.Q58714451

P2860

Q26738390-EC6FC665-E4E9-46A8-812F-C62A55C4F430 Q26738986-0C335FAA-433C-4838-96E8-3CE73C18D3DC Q28071903-DE7201D0-BC8C-49E5-A20D-0039268A1917 Q33582635-3A182EB2-4123-4AA1-9902-6396BF89C0C0 Q33648864-1F8202DE-E594-47ED-A4CB-C9A5FCA6C61B Q33730022-6515E2D3-F3D8-4E9B-834A-A4044D762B35 Q36948934-A4870BDC-6490-42AE-8C93-0214DF3F608F Q37269159-3218A364-096E-4433-B80E-217615791DAE Q37413101-131ECE1F-9071-453E-9F69-749ABC9009E1 Q37580410-12242657-0740-44A0-A51A-7A63E9245F33 Q37662206-6673ECEF-A083-4AA6-8285-4C934B611C7A Q37662209-56FC1382-58BA-4991-8785-E84ED309497F Q37696243-710663FD-CDCF-42C5-A6EE-6B8753A6548D Q37698613-6028C18F-BC85-4868-BD96-1DC10A866EE5 Q38671947-598D8EBA-62AF-4036-974F-D4EB5C950AEF Q38702793-81346528-B135-449E-950B-BB62F46D7558 Q38828319-9323950E-02A0-4009-B884-13A4F8AE3FFA Q38846823-BEA03A7F-43E6-4F11-B95E-5F5FDA809CED Q40518308-A34DA358-3E01-4854-BA0F-3AB95CD89E89 Q40986813-6AA16D8C-35DF-4C41-8EC6-BDB58CAC98C2 Q41037400-B6F9764C-7CE6-41EE-A16B-C84CC15479D3 Q41233667-D6A30A7F-5C86-4578-9B17-37A701EAD176 Q41475904-DE58FDC7-A818-404E-9841-A55374B8C75C Q42398711-4EA90608-2A21-427E-8983-6C621EDB4888 Q46611738-28B8886C-C8DF-4801-A08A-62E54ADE472D Q47260594-CD054B8A-FD09-419A-AAF4-588BC76E637E Q48108243-87E7BF34-DFE7-4180-B50A-6F1F283932D0 Q48505939-65F01BD7-1FBE-498F-A55D-502B0285C00C Q50452212-C2685D76-9B3B-4E1E-8FBB-91928FA71BBA Q50525080-A50A29E8-5D42-4DCD-9B92-EC8FC916ECB5 Q53682041-16757DA2-2880-4092-9CC7-3D57B1D14D0D Q54981628-CB967BC0-1E32-44B9-8D65-A1CA9844ECB7 Q58714451-340DA1B7-8F08-4116-8A20-90AD717574C5

P2860

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

http://www.wikidata.org/entity/Q35791225

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

@ast

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

@en

type

label

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

@ast

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

@en

prefLabel

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

@ast

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

@en

P1433

Q35791225-1E9E4762-8B6B-4F23-BBB8-2C8ECDBEEB2C

P1476

Q35791225-ADFD5FA5-2AEF-4DFA-87C6-ADF5D256E1E8

P2093

Q35791225-18AFEF3E-69EF-4559-8615-33617BBB2124

Q35791225-1B6604F1-481D-4553-9690-699F80CF7190

Q35791225-482F2099-B40D-4ADB-A792-4E386915B988

Q35791225-5C27A4DB-4A97-4FF5-A640-5F6675EB5D88

Q35791225-73CD3D76-8DA8-477B-9EED-BAF11A564161

Q35791225-B8D69F7F-4FB3-4293-9A4A-0442A0FF8004

Q35791225-D6875848-9CE0-4251-913B-56465CA7EE44

Q35791225-DB301327-0FDA-47B6-98C5-609FC6433A7D

Q35791225-F4E786CA-D44C-4788-8F55-094522FF127A

Q35791225-F71C9AA7-34F8-493A-B7E8-9C78408206CB

P2860

Q35791225-028DA13D-F3D1-4C7C-B076-0442B294EA9D

Q35791225-04CF5611-A4A7-4754-B457-3DD00FFFF02C

Q35791225-065B2E69-C10D-4C00-B0B7-AD2B27F1342F

Q35791225-09BDE178-047D-4690-9253-F45E110782B6

Q35791225-10B006F3-727D-460E-B983-7D30B05013C9

Q35791225-19527912-2922-4DC5-9B99-98D76B68A417

Q35791225-1AD45E58-3DCC-463B-8AF2-1D8071564EBD

Q35791225-29AE6EA1-175C-4B74-89CE-EEE006A0DA99

Q35791225-331F657D-7925-4254-937A-5E0CADEBD98E

Q35791225-40EE1899-0848-4A6F-9CFA-5AFD3C8CA8F6

P304

Q35791225-E9EEF79A-2F72-42D1-883C-43A1694ABF21

P31

Q35791225-1DA87204-5553-4898-AF6C-3F42E0405BF3

P356

Q35791225-A7B88D1D-A5CB-4EDA-AB2E-EB4D0759478B

P407

Q35791225-D0FA237B-EC82-4F2D-95F5-834834D23322

P433

Q35791225-5063F8A1-2FA4-48AB-A887-6076E6B28D2C

P478

Q35791225-34648E7B-F183-45BB-991E-73554EF9070F

P577

Q35791225-09908F81-633C-4FCC-A5B5-B0D36BA97EEB

P698

Q35791225-D6DF6C15-2C34-403A-8E36-2AB9C0C0F2DC

P921

Q35791225-0A4D38B3-EDB1-45B5-BC9E-51F103926AAB

P932

Q35791225-3256ED9A-2BEB-40C1-89AE-1B3E19AC1759

P356

JCO.2014.58.8293

P1433

Journal of Clinical Oncology

P1476

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

@en

P2093

Caicun Zhou

http://www.w3.org/2001/XMLSchema#string

Chao Zhao

http://www.w3.org/2001/XMLSchema#string

Chunyan Wu

http://www.w3.org/2001/XMLSchema#string

Dongmei Lin

http://www.w3.org/2001/XMLSchema#string

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Ke Fei

http://www.w3.org/2001/XMLSchema#string

Limou Zheng

http://www.w3.org/2001/XMLSchema#string

Shannon Chuai

http://www.w3.org/2001/XMLSchema#string

Weijing Cai

http://www.w3.org/2001/XMLSchema#string

Xuefei Li

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Genome remodelling in a basal-like breast cancer metastasis and xenograft

Tumour evolution inferred by single-cell sequencing

Inferring tumor progression from genomic heterogeneity

Clonal evolution in cancer

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Intra-tumour heterogeneity: a looking glass for cancer?

Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

P304

3701-3709

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.58.8293

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26416997

http://www.w3.org/2001/XMLSchema#string

P921

P932

4770798

http://www.w3.org/2001/XMLSchema#string